Georgia Health Sciences University Research Institute, Inc.
|Georgia Health Sciences University Research Institute, Inc. Patent applications|
|Patent application number||Title||Published|
|20130236456||IMMUNOGLOBULIN Fc FRAGMENT TAGGING ACTIVATION OF ENDOGENOUS CD4 AND CD8 T CELLS AND ENHANCEMENT OF ANTITUMOR EFFECTS OF LENTIVECTOR IMMUNIZATION - A lentivector has been engineered to express a fusion antigen composed of hepatitis B surface protein (HBsAg) and IgG2a Fc fragment (HBS-Fc-Iv) to increase both the magnitude of CD8 response and to induce effective co-activation of CD4 T cells. Immunization with this HBS-Fc-Iv caused significant regression of established tumors. Immunological analysis revealed that, compared to HBS-Iv without the Fc fragment, immunization with HBS-Fc-Iv markedly increased the number of functional CD8 and CD4 T cells and the level of Th1/Tc1-like cytokines in the tumor, while substantially decreasing the Treg ratio. The favorable immunologic changes in tumor lesions and the improvement of antitumor effects from HBS-Fc-Iv immunization were dependent on the CD4 activation, which was Fc receptor mediated. Adoptive transfer of the CD4 T cells from the HBS-Fc-Iv immunized mice could activate endogenous CD8 T cells in an IFNγ-dependent manner. Endogenous CD4 T cells can be activated by lentivirus expressing Fc-tagged antigen to provide another layer of help, i.e., creating a Th1/Tc1 like pro-inflammatory milieu within the tumor lesion to help the effector phase of immune responses to enhance the antitumor effect.||09-12-2013|
|20130230512||INHIBITORS OF THE ATB(0,+) TRANSPORTER AND USES THEREOF - The present invention includes inhibitors of the amino acid transporter ATB||09-05-2013|
|20130212715||Biomarkers for Hematologic Malignacies - It has been discovered that STAT5 phosphorylation and CD150 are effective biomarkers for detecting, diagnosing, and monitoring hematological malignancies, including for example lymphomas. Compositions and methods for identifying therapeutic agents for the treatment of hematologic malignancies using p-STAT5, CD150 or both as biomarkers are described.||08-15-2013|
|20130009372||WHEELCHAIR ATTACHMENT WITH SELECTIVELY DEPLOYABLE SECONDARY FRONT WHEELS - An attachment for a wheelchair includes a secondary front-wheel pair that is movable from a disengaged up position, to a deployed down position, and back again. In the disengaged up position, the secondary front wheels are up off the ground, so the primary front wheels of the wheelchair are in contact with the ground and thereby being used. In the deployed down position, the secondary front wheels are down in contact with the ground and are thereby being used, so the primary front wheels are now removed from contact with the ground and are no longer in use. In typical embodiments, the secondary front wheels are relatively larger wheels for traversing rough terrain, the primary front wheels are relatively smaller wheels for traversing smooth terrain, and the secondary front wheels move between the disengaged up position and the deployed down position in a pivoting motion.||01-10-2013|
|20120219568||EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER - Compositions containing epidithiodioxopiprazines and methods of their use are provided. Epidithiodioxopiprazines can be isolated from natural resources or synthesized de novo. Moreover, epidithiodioxopiprazines, including Verticillin A, are shown to effectively sensitize multiple types of tumor cells to TRAIL-induced apoptosis. In addition, epidithiodioxopiprazines, including Verticillin A, are shown to effectively overcome cancer cell resistance to existing drugs (i.e. Etoposide, Cisplatin, 5-FU and Doxorubicin). Therefore, compositions and methods are provided for use in sensitizing target cancer cells to death receptor- and other anticancer drugs-induced apoptosis. Methods of treating cancer in a subject in need thereof are also provided.||08-30-2012|
|20120201892||POROUS-WALL HOLLOW GLASS MICROSPHERES AS CARRIERS FOR BIOMOLECULES - The present invention includes compositions of porous-wall hollow glass microspheres and one or more biomolecules, wherein the one or more biomolecules are positioned within a void location within the hollow glass microsphere, and the use of such compositions for the diagnostic and/or therapeutic delivery of biomolecules.||08-09-2012|
Patent applications by Georgia Health Sciences University Research Institute, Inc.